Basal Tumours in Bladder Cancer, Response to chemoTherapy (BoBCaT)

University Hospital, Rouen

Status: Completed

Conditions: Chemotherapy Effect; Bladder Cancer

Treatments: Combination Product: neoadjuvant chemotherapy with cisplatine

Study type: Observational

Funder types: Other

Identifiers

NCT04089748

2016/384/HP

Details and patient eligibility

About

Determine the sensitivity/resistance to chemotherapy of the various subgroups of muscle-invasive bladder cancers, including the basal subgroup (about 25% of these tumours) according to 4 different classifications based on molecular or immunohistochemical classifiers.

Enrollment: 293 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria of Patients enrolled in VESPER study:

Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in VESPER cohort and :

• having signed an informed consent form for the participation to the collection or
• dead/lost to follow-up without prior opposition expressed against research program,
• genetic analysis will only be carried out for patients who have signed the genetic consent form.

Inclusion Criteria of Patients from St Louis cohort not enrolled in VESPER study:

Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in Saint-Louis cohort and :

• having received an informed form for the participation to the collection and not having expressed opposition against research program within 1 month or
• dead/lost to follow-up without prior opposition expressed against research program,

Exclusion Criteria:

-Patients enrolled in VESPER study:Tumors from patient having withdrawn his/her informed consent form for the participation to the collection and/or VESPER project.

OR

-Patients from St Louis not enrolled in VESPER study:Tumors from patient having expressed opposition against research program after 1 month for the participation to the collection.

Trial design

293 participants in 2 patient groups

Patients enrolled in VESPER study

Description:

Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in VESPER cohort

Treatment:

Combination Product: neoadjuvant chemotherapy with cisplatine

Patients from St Louis cohort not enrolled in VESPER study

Description:

Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in Saint-Louis cohort

Treatment:

Combination Product: neoadjuvant chemotherapy with cisplatine